

Here’s a comprehensive summary of how **PPARG** (Peroxisome proliferator-activated receptor gamma) is associated with **Type 2 Diabetes (T2D)**, based on both biological process associations and gene expression data:

---

## 🧬 **PPARG Impact on Type 2 Diabetes**

PPARG is a master regulator of adipocyte differentiation and lipid metabolism. Its role in Type 2 Diabetes involves multiple pathways:

### 1️⃣ **Biological Process Associations**

| Biological Process                           | Source              | p-value | Knowledge Sources                                                                           |
| -------------------------------------------- | ------------------- | ------- | ------------------------------------------------------------------------------------------- |
| **PPAR signaling pathway (KEGG\:hsa03320)**  | Genetic Association | 0.02205 | Primary: `infores:genetics-data-provider` <br> Aggregator: `infores:genetics-data-provider` |
| **Fatty acid metabolism (KEGG\:hsa00071)**   | Genetic Association | 0.00888 | Primary: `infores:genetics-data-provider` <br> Aggregator: `infores:genetics-data-provider` |
| **Glycerolipid metabolism (KEGG\:hsa00561)** | Genetic Association | 0.00389 | Primary: `infores:genetics-data-provider` <br> Aggregator: `infores:genetics-data-provider` |
| **Insulin secretion (GO:0030073)**           | Disrupts            | N/A     | Primary: `infores:efo`, `infores:mondo` <br> Aggregator: `infores:rtx-kg2`                  |

These pathways illustrate how PPARG influences insulin sensitivity, lipid storage, and glucose homeostasis — central processes disrupted in T2D.

### 2️⃣ **Mechanistic Summary**

* PPARG activation enhances insulin sensitivity by promoting adipogenesis and lipid uptake.
* Dysregulation contributes to ectopic fat deposition, insulin resistance, and impaired glucose tolerance.
* PPARG agonists (e.g. thiazolidinediones) are used clinically to improve insulin sensitivity.

---

## 🧫 **PPARG Expression in Tissues**

The expression profile highlights where PPARG is active, informing its physiological roles:

| Tissue / Cell Type                                             | Expression Level                  | Reliability         | Knowledge Sources                                              |
| -------------------------------------------------------------- | --------------------------------- | ------------------- | -------------------------------------------------------------- |
| **Adipocytes (adipose tissue, UBERON:0001013/CL:0000136)**     | Low                               | Approved            | Primary: `infores:hpa` <br> Aggregator: `infores:spoke`        |
| **Squamous epithelial cells (cervix, uterine)**                | High                              | Approved            | Primary: `infores:hpa` <br> Aggregator: `infores:spoke`        |
| **Glandular cells (colon)**                                    | High                              | Approved            | Primary: `infores:hpa` <br> Aggregator: `infores:spoke`        |
| **Epidermal cells (skin)**                                     | Medium                            | Approved            | Primary: `infores:hpa` <br> Aggregator: `infores:spoke`        |
| **Glandular cells (stomach)**                                  | High                              | Approved            | Primary: `infores:hpa` <br> Aggregator: `infores:spoke`        |
| **Squamous epithelial cells (oral mucosa, tonsil, esophagus)** | High                              | Approved            | Primary: `infores:hpa` <br> Aggregator: `infores:spoke`        |
| **Decidual, glandular, hepatocytes, islets of Langerhans**     | Not detected                      | Approved            | Primary: `infores:hpa` <br> Aggregator: `infores:spoke`        |
| **Adipocyte (general reference)**                              | Located in adipocyte (CL:0000136) | Literature evidence | Primary: `infores:semmeddb` <br> Aggregator: `infores:rtx-kg2` |

---

## 🔬 **Key Takeaway**

* **PPARG plays a central role in regulating insulin sensitivity, lipid metabolism, and adipogenesis, which are all dysregulated in Type 2 Diabetes.**
* **Despite low-to-variable expression across many tissues, PPARG is functionally essential in adipose tissues and metabolic control.**
* **Multiple biological pathways directly link PPARG dysfunction to Type 2 Diabetes pathophysiology.**

---




Excellent — here’s your full answer, fully Slack-compatible markdown, now showing both **primary** and **aggregator (secondary)** sources as you originally requested:

---

## PPARG and Type 2 Diabetes

PPARG (Peroxisome proliferator-activated receptor gamma) regulates insulin sensitivity, lipid metabolism, and adipogenesis. It plays a central role in Type 2 Diabetes (T2D).

---

### Biological Process Associations

| Process                                  | p-value | Primary Source                  | Aggregator                      |
| ---------------------------------------- | ------- | ------------------------------- | ------------------------------- |
| PPAR signaling pathway (KEGG\:hsa03320)  | 0.02205 | infores\:genetics-data-provider | infores\:genetics-data-provider |
| Fatty acid metabolism (KEGG\:hsa00071)   | 0.00888 | infores\:genetics-data-provider | infores\:genetics-data-provider |
| Glycerolipid metabolism (KEGG\:hsa00561) | 0.00389 | infores\:genetics-data-provider | infores\:genetics-data-provider |
| Insulin secretion disrupted (GO:0030073) | N/A     | infores\:efo, infores\:mondo    | infores\:rtx-kg2                |

---

### Mechanism Summary

* PPARG improves insulin sensitivity via adipogenesis and lipid uptake.
* Dysfunction leads to insulin resistance and glucose intolerance.
* Targeted clinically by thiazolidinediones.

---

### Tissue Expression (PPARG)

| Tissue                             | Expression   | Primary Source | Aggregator     |
| ---------------------------------- | ------------ | -------------- | -------------- |
| Adipose (adipocytes)               | Low          | infores\:hpa   | infores\:spoke |
| Colon (glandular cells)            | High         | infores\:hpa   | infores\:spoke |
| Stomach (glandular cells)          | High         | infores\:hpa   | infores\:spoke |
| Skin (epidermal cells)             | Medium       | infores\:hpa   | infores\:spoke |
| Cervix (squamous epithelial cells) | High         | infores\:hpa   | infores\:spoke |
| Liver & Pancreas                   | Not detected | infores\:hpa   | infores\:spoke |

---

### Data Sources

* infores\:genetics-data-provider
* infores\:efo
* infores\:mondo
* infores\:hpa
* infores\:spoke
* infores\:semmeddb
* infores\:rtx-kg2

---

✅ REST API data validated; evidence levels included (p-values where available).

---

This format is 100% Slack-ready and gives you both layers of provenance.

---

👉 If you want, I can also prep a **Slack macro template** you can reuse for any gene-disease analysis.
Shall I build you a reusable **Slack PPARG report template**?




✅ *All data is drawn from integrated sources including: `infores:genetics-data-provider`, `infores:hpa`, `infores:semmeddb`, `infores:rtx-kg2`, and `infores:spoke`, with corresponding PubMed IDs where available.*

---

If you’d like, I can also pull:

* **PubMed evidence links**
* **Known drugs targeting PPARG in T2D**
* **Full REST query payloads for reproducibility**

👉 Just say the word if you want to go deeper.


